Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 11, Issue 6, Pages 567-577Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/ERM.11.45
Keywords
biomarker; clinical information; nonresponders; oncology; predictive medicine; targeted therapy
Categories
Ask authors/readers for more resources
While current trials of anticancer agents serve to provide a population-based validation of therapeutic activity, clinical success is typically restricted to tumors of select molecular subtype. Recent insights have yielded a growing catalogue of germline and tumor-based aberrations that can predetermine whether a patient will achieve clinical benefit from a drug or not. Thus, in order to realize the true potential of anticancer agents, we need to define the molecular contexts under which they will prove both efficacious and safe. In this article, we provide an overview of such molecular determinants and introduce the concept of 'cancer patient profiling' - the process and science of defining the optimal therapy for a given patient through the generation and analysis of system-wide molecular information.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available